Top Markets
#1 Black Phoenix Black Phoenix +166.09%
#2 Islamic Coin Islamic Coin +158.29%
#3 Glidr Glidr +58.56%
#4 DOVU DOVU +20.73%
#5 Cryptopia Cryptopia +20.42%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.03%
#7 MarsCoin MarsCoin +10.05%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.23%
#9 Pons Pons +8.66%
#10 stake.link stake.link +8.27%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Sienna Biopharmaceuticals, Inc. Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc.

SNNAQ
Rank in Stocks #42234
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm... Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$3.09K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Sienna Biopharmaceuticals, Inc. (SNNAQ)

Category

Healthcare
Revenue for Sienna Biopharmaceuticals, Inc. (SNNAQ)
Revenue in Aug 2026 TTM: 0
According to Sienna Biopharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sienna Biopharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR